Question 1

Who are the top researchers at Resverlogix (Canada)?

Accepted Answer

Ranked on the quality score, Jan O. Johansson, Ravi Jahagirdar and Li Fu lead among researchers whose main affiliation is Resverlogix (Canada).

Question 2

What are the most cited papers from Resverlogix (Canada)?

Accepted Answer

The most cited paper from Resverlogix (Canada) is "BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection" (Richard J. Mills et al., 2021), with 240 citations. Next come "RVX-208" (233) and "RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist" (201).

Question 3

Which research topics does Resverlogix (Canada) publish most on?

Accepted Answer

By volume in 2022-now: Protein Degradation and Inhibitors, Heart Failure Treatment and Management, Chromatin Remodeling and Cancer and Peptidase Inhibition and Analysis.

Question 4

Which keywords describe research at Resverlogix (Canada)?

Accepted Answer

By fractional works in all years, weighted toward what it does more of than the world: Transcriptional Regulation, BET Bromodomains, PROTACs, Cancer Therapy, Obesity, Metabolic Syndrome, Cardiovascular Disease and Inflammation.

Question 5

Which fields of science does Resverlogix (Canada) work in?

Accepted Answer

In all years, 46% of research at Resverlogix (Canada) is in Life Sciences, 39% in Health Sciences. Its largest fields are Biochemistry, Genetics and Molecular Biology (39%), Medicine (38%), Social Sciences (5%). It does 2.6× the world's share of Life Sciences.

Question 6

Is Resverlogix (Canada)'s research output growing?

Accepted Answer

Output in 2022-2025 was 57% lower than in 2018-2021.